Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Feurstein

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Wiener Medizinische Wochenschrift (1946)|January 29, 2021
New therapeutic options for bone diseasesRoland Kocijan, Judith Haschka, Julia Feurstein, et al.
JBMR Plus|September 3, 2024
Longitudinal course of circulating miRNAs in a patient with hypophosphatasia and asfotase alfa treatment: a case reportBenjamin Hadzimuratovic, Judith Haschka, Matthias Hackl, et al.
Orphanet Journal of Rare Diseases|December 13, 2022
Identifying adult hypophosphatasia in the rheumatology unitJulia Feurstein, Martina Behanova, Judith Haschka, et al.
The Journal of Clinical Endocrinology and Metabolism|February 11, 2025
Circulating Micro-RNAs in Patients with Hypophosphatasia Results of the first micro-RNA analysis in HPPJudith Haschka, Zora Messner, Julia Feurstein, et al.
Wiener Klinische Wochenschrift|August 29, 2022
National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)Eva Rath, Michael Bonelli, Christina Duftner, et al.
Zeitschrift Fur Rheumatologie|November 7, 2022
[National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs)]Eva Rath, Michael Bonelli, Christina Duftner, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Wiener Medizinische Wochenschrift (1946)|January 29, 2021
New therapeutic options for bone diseasesRoland Kocijan, Judith Haschka, Julia Feurstein, et al.
JBMR Plus|September 3, 2024
Longitudinal course of circulating miRNAs in a patient with hypophosphatasia and asfotase alfa treatment: a case reportBenjamin Hadzimuratovic, Judith Haschka, Matthias Hackl, et al.
Orphanet Journal of Rare Diseases|December 13, 2022
Identifying adult hypophosphatasia in the rheumatology unitJulia Feurstein, Martina Behanova, Judith Haschka, et al.
The Journal of Clinical Endocrinology and Metabolism|February 11, 2025
Circulating Micro-RNAs in Patients with Hypophosphatasia Results of the first micro-RNA analysis in HPPJudith Haschka, Zora Messner, Julia Feurstein, et al.
Wiener Klinische Wochenschrift|August 29, 2022
National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)Eva Rath, Michael Bonelli, Christina Duftner, et al.
Zeitschrift Fur Rheumatologie|November 7, 2022
[National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs)]Eva Rath, Michael Bonelli, Christina Duftner, et al.
Pageof 1